Cardiovascular Disease: Consultation on the Draft Scope (23rd April 2008)
NICE was asked by the Department of Health to develop guidance on the prevention of cardiovascular disease at the population level. All registered stakeholders for the above public health programme guidance are invited to comment on the draft scope. Closing date for comments is 22nd May 2008.
Click here for the Draft Scope
Click here for the Comments Form
Psoriasis - adalimumab: final appraisal determination (25th April 2008)
This guidance was developed using the single technology appraisal (STA) process. Adalimumab is recommended as a treatment option for adults with plaque psoriasis for whom anti-tumour necrosis factor (TNF) treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10; and The psoriasis has not responded to standard systemic therapies including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation); or the person is intolerant of, or has a contraindication to, these treatments.
Click here for the Guidance
Implantation of miniature lens system for advanced age-related macular degeneration (interventional procedures consultation) (24th April 2008)
Age-related macular degeneration is an eye disorder affecting central vision that usually occurs in later life. The procedure involves removing the natural lens of the eye through a small incision at the front of the eye and implanting a combination of artificial lenses with the aim of helping to improve central vision. The National Institute for Health and Clinical Excellence is examining implantation of miniature lens systems for advanced age-related macular degeneration and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland. The Institute's Interventional Procedures Advisory Committee has considered the available evidence and the views of Specialist Advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about implantation of miniature lens systems for advanced age-related macular degeneration. Closing date for comments is 23rd May 2008.
Click here for the Consultation
NICE was asked by the Department of Health to develop guidance on the prevention of cardiovascular disease at the population level. All registered stakeholders for the above public health programme guidance are invited to comment on the draft scope. Closing date for comments is 22nd May 2008.
Click here for the Draft Scope
Click here for the Comments Form
Psoriasis - adalimumab: final appraisal determination (25th April 2008)
This guidance was developed using the single technology appraisal (STA) process. Adalimumab is recommended as a treatment option for adults with plaque psoriasis for whom anti-tumour necrosis factor (TNF) treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10; and The psoriasis has not responded to standard systemic therapies including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation); or the person is intolerant of, or has a contraindication to, these treatments.
Click here for the Guidance
Implantation of miniature lens system for advanced age-related macular degeneration (interventional procedures consultation) (24th April 2008)
Age-related macular degeneration is an eye disorder affecting central vision that usually occurs in later life. The procedure involves removing the natural lens of the eye through a small incision at the front of the eye and implanting a combination of artificial lenses with the aim of helping to improve central vision. The National Institute for Health and Clinical Excellence is examining implantation of miniature lens systems for advanced age-related macular degeneration and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland. The Institute's Interventional Procedures Advisory Committee has considered the available evidence and the views of Specialist Advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about implantation of miniature lens systems for advanced age-related macular degeneration. Closing date for comments is 23rd May 2008.
Click here for the Consultation
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use): (appraisal consultation document) (29th April 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after the failure of a TNF-alpha inhibitor and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after the failure of a TNF-alpha inhibitor. Closing date for comments is 20th May 2008.
Click here for Consultation
No comments:
Post a Comment